Chewy, Inc. — Form 10-Q Summary
Period: The filing covers the 13 weeks ended April 28, 2024, compared with the 13 weeks ended April 30, 2023. Although the request metadata says “2023 Q1,” the filing itself is for fiscal 2024 Q1. Amounts below are U.S. dollars.
Business context
Chewy operates an e-commerce business selling pet products and services through its websites and mobile applications. Its offerings include Autoship subscriptions, pharmacy and other pet-health products, and private-brand products. The company reported that comparative periods were recast to include Chewy Pharmacy KY following its acquisition as a wholly owned subsidiary in the October 2023 transactions with BC Partners affiliates.
Financial and operating results
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $2.878 billion | $2.791 billion | +3.1% |
| Gross profit / gross margin | $854.0 million / 29.7% | $792.9 million / 28.4% | Margin +130 bps |
| Operating income / margin | $64.6 million / 2.2% | $24.7 million / 0.9% | +161.2% |
| Net income / net margin | $66.9 million / 2.3% | $22.9 million / 0.8% | +192.7% |
| Adjusted EBITDA / margin | $162.9 million / 5.7% | $110.9 million / 4.0% | +46.9% |
| Operating cash flow | $81.9 million | $148.7 million | -44.9% |
| Free cash flow | $52.6 million | $127.1 million | -58.6% |
Basic and diluted GAAP EPS were each $0.15, versus $0.05. Adjusted diluted EPS was $0.31, versus $0.20. Adjusted EBITDA, adjusted net income, adjusted EPS and free cash flow are non-GAAP measures; the filing provides reconciliations and cautions that these measures have limitations.
Active customers declined 2.1% to 19.988 million. Net sales per active customer increased 9.6% to $562. Autoship customer sales rose 6.4% to $2.233 billion and represented 77.6% of sales, compared with 75.2%. By category, consumables sales grew 2.1%, hardgoods declined 2.1%, and other sales grew 10.7%.
Liquidity, debt and cash flow
At April 28, 2024, cash and cash equivalents were $1.135 billion and marketable securities were $3.5 million, compared with $602.2 million and $531.8 million, respectively, at January 28, 2024. The increase in cash largely reflects $535.0 million of marketable-security maturities; investing cash flow was $505.7 million. Operating cash flow fell year over year, primarily because working capital used cash, including through lower accrued liabilities and higher inventory and receivables. Capital expenditures were $29.3 million, versus $21.6 million.
Chewy had no borrowings under its $800 million asset-based revolving credit facility and reported $759.4 million of available borrowing capacity, subject to its borrowing base. Current assets were $2.126 billion and current liabilities were $1.996 billion. Operating lease liabilities totaled $549.7 million; finance lease obligations were not material. Management said available cash, securities and credit-facility capacity should fund working capital, capital expenditures and contractual obligations for at least the next 12 months.
Material changes and management commentary
- Gross margin improved as sales growth outpaced cost-of-goods-sold growth; management cited supply-chain efficiencies and margin expansion in consumables, healthcare and private brands.
- SG&A increased 3.1%, mainly due to higher share-based compensation and facilities and general expenses, partly offset by lower fulfillment costs from automation and supply-chain efficiencies. Advertising and marketing increased 1.7%, including investment in marketing channels and Canada expansion.
- Net income benefited from stronger gross profit, higher net interest income and lower other expense. The year-ago period included a larger equity-warrant fair-value loss.
- Share-based compensation and related taxes were $69.5 million for the quarter and are excluded from certain adjusted measures. The filing reports $700.7 million of unrecognized RSU compensation expense expected to be recognized over a weighted-average 2.9 years.
- The company paid $54.8 million of net taxes related to the parent reorganization transaction in financing activities. It also reported $1.9 billion of assumed transaction-related income taxes indemnified by BC Partners affiliates, subject to disclosed terms; the filing describes indemnification for future tax exposure up to $196 million, with excess exposure the company’s responsibility.
- The company maintains a $281.1 million valuation allowance against net deferred tax assets. Management said there is a reasonable possibility of releasing a significant portion related to U.S. entities within 12 months, depending on profitability; timing and amount remain uncertain.
Outlook, risks and contingencies
The filing gives no numerical sales, earnings or margin guidance. Management noted continuing uncertainty from inflation, interest rates and consumer behavior and said it is adapting logistics, supply-chain and purchasing processes. It identifies risks including competition and customer retention, supplier and shipping disruptions, fulfillment capacity, cybersecurity and third-party technology dependence, regulation of pharmacy and veterinary services, and potential effects of severe weather and international trade restrictions.
Chewy said it believes pending legal matters are adequately accrued where losses are probable and estimable and does not expect the matters to have a material adverse effect, while noting outcomes cannot be predicted with certainty. In the IBM patent dispute, the parties filed a joint stipulation voluntarily dismissing all claims and counterclaims on March 25, 2024. Management concluded disclosure controls were effective at a reasonable assurance level as of April 28, 2024; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Whether sales growth and higher spending per active customer can offset the decline in active customers.
- Whether improved gross and operating margins persist, particularly as marketing, share-based compensation and expansion costs continue.
- Why operating cash flow and free cash flow fell materially year over year, and how working-capital movements develop in subsequent quarters.
- The terms, collection and coverage limits of BC Partners tax indemnities, and whether the deferred-tax valuation allowance is released.
- Progress, costs and returns from Canada expansion and investment in pharmacy facilities, veterinary clinics and fulfillment capacity.
- Any changes to credit-facility availability, share repurchases, or the risks arising from controlling-stockholder ownership and the dual-class share structure.